Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
Want to see TNYA full AI Analyst Report?
TNYA Stock Chart & Stats
$1.33
-$0.05(-3.69%)
At close: 4:00 PM EST
$1.33
-$0.05(-3.69%)
Day’s Range― - ―
52-Week Range$0.36 - $2.35
Previous CloseN/A
Volume1.07M
Average Volume (3M)4.00M
Market Cap
$145.87M
Enterprise Value$26.91M
Total Cash (Recent Filing)$100.55M
Total Debt (Recent Filing)$10.83M
Price to Earnings (P/E)―
Beta2.48
Next Earnings
May 13, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding216,998,870
10 Day Avg. Volume2,873,734
30 Day Avg. Volume4,003,933
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.88
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.32
Forecast
1Y Price Target
$4.75Price Target Upside257.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DataClinical data for TN-401 showed consistent links between increased PKP2 levels and clearer improvements in arrhythmic measures, reinforcing the program's therapeutic rationale.
PartnershipCollaboration with Alnylam assigns development and commercialization of discovered RNAi targets to a well-capitalized partner, providing non-dilutive funding and external validation of the discovery platform.
Pipeline DiversificationPreclinical TN-301 results demonstrated restoration of muscle performance and correction of Duchenne-derived cardiac cell defects with a clean safety and selectivity profile, creating a differentiated small-molecule asset beyond gene therapy.
Bears Say
Biomarker UncertaintyLack of a validated biomarker for target protein replacement complicates biopsy interpretation and hinders reliable assessment of treatment effect in clinical studies.
Clinical Data LimitationsVery few patients and limited clinical data across gene therapy programs make head-to-head comparisons difficult and increase uncertainty about which candidate will deliver a clear clinical benefit.
Financial RiskHigh cash burn and a constrained cash runway elevate financing risk and could pressure program advancement unless additional funding is secured.
Tenaya Therapeutics News
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.36 and its highest was $2.35 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $145.87M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 15 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on Mar 11, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.121 by $0.001.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 216,998,870 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.121. Following the earnings report the stock price went up 3.963%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenaya Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.75 (257.14% Upside)
$4.75 (257.14% Upside)
Hedge Fund Trend
Increased
By 178.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.73%
12-Months-Change
Fundamentals
Return on Equity
-85.20%
Trailing 12-Months
Asset Growth
21.07%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
TNYA Stock 12 Month Forecast
Average Price Target
$4.75
▲(257.14% Upside)
Technical Analysis
Galectin Therapeutics
―
Abeona Therapeutics
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Candel Therapeutics
―
Ownership Overview
50.40% Insiders
4.27% Mutual Funds
0.95% Other Institutional Investors
39.79% Public Companies and Individual Investors